Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) had Normalized Income after Taxes of $-10.60M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-10.58M |
|
-- |
|
-- |
|
$11.02M |
|
$-11.02M |
|
$0.40M |
|
$-10.62M |
|
$-10.62M |
|
$-10.60M |
|
$-10.60M |
|
$-10.60M |
|
|
Normalized Income after Taxes |
$-10.60M |
$-11.02M |
|
$-10.20M |
|
40.85M |
|
40.85M |
|
$-0.26 |
|
$-0.26 |
|
| Balance Sheet Financials | |
$63.27M |
|
$3.04M |
|
$18.62M |
|
$81.89M |
|
$11.42M |
|
-- |
|
$13.34M |
|
$24.76M |
|
$57.13M |
|
$44.09M |
|
$57.13M |
|
40.85M |
|
| Cash Flow Statement Financials | |
$-11.46M |
|
$0.12M |
|
-- |
|
$71.85M |
|
$59.63M |
|
$-12.22M |
|
$0.99M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.54 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-11.34M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-18.55% |
|
-24.04% |
|
-12.94% |
|
-18.55% |
|
$1.40 |
|
$-0.28 |
|
$-0.28 |
|